8 引文 (Scopus)

摘要

Ovarian cancer has a poor prognosis. Most patients are diagnosed with ovarian cancer when the disease has reached an advanced stage and cure rates are generally under 30%. Hence, early diagnosis of ovarian cancer is the best means to control the disease in the long term and abate mortality. So far, cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) are the gold-standard tumor markers for ovarian cancer; however, these two markers can be elevated in a number of conditions unrelated to ovarian cancer, resulting in decreased specifically and positive predictive value. Therefore, it is urgent to identify novel biomarkers with high reliability and sensitivity for ovarian cancer. In this study for the first time, we identified a member of the centromere protein (CENP) family, CENPK, which was specifically upregulated in ovarian cancer tissues and cell lines and the overexpression of which was associated with poor prognoses in patients with ovarian cancer. In addition, the presence of CENPK significantly improved the sensitivity of CA125 or HE4 for predicting clinical outcomes of ovarian cancer patients. In conclusion, we identified that CENPK was specifically upregulated in ovarian cancer cells and can be used as a novel tumor marker of ovarian cancer.
原文英語
頁(從 - 到)e1386
期刊PeerJ
3
DOIs
出版狀態已發佈 - 2015

指紋

ovarian neoplasms
Centromere
centromeres
Ovarian Neoplasms
Tumor Biomarkers
Survival
Cells
Antigens
Proteins
proteins
Biomarkers
Gold
neoplasms
Tissue
Epididymis
epididymis
prognosis
protein K
antigens
early diagnosis

引用此文

@article{5b6c56777750410c8dbc95dd1d45f21b,
title = "Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance",
abstract = "Ovarian cancer has a poor prognosis. Most patients are diagnosed with ovarian cancer when the disease has reached an advanced stage and cure rates are generally under 30{\%}. Hence, early diagnosis of ovarian cancer is the best means to control the disease in the long term and abate mortality. So far, cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) are the gold-standard tumor markers for ovarian cancer; however, these two markers can be elevated in a number of conditions unrelated to ovarian cancer, resulting in decreased specifically and positive predictive value. Therefore, it is urgent to identify novel biomarkers with high reliability and sensitivity for ovarian cancer. In this study for the first time, we identified a member of the centromere protein (CENP) family, CENPK, which was specifically upregulated in ovarian cancer tissues and cell lines and the overexpression of which was associated with poor prognoses in patients with ovarian cancer. In addition, the presence of CENPK significantly improved the sensitivity of CA125 or HE4 for predicting clinical outcomes of ovarian cancer patients. In conclusion, we identified that CENPK was specifically upregulated in ovarian cancer cells and can be used as a novel tumor marker of ovarian cancer.",
keywords = "Journal Article",
author = "Yi-Chao Lee and Chi-Chen Huang and Ding-Yen Lin and Wen-Chang Chang and Kuen-Haur Lee",
year = "2015",
doi = "10.7717/peerj.1386",
language = "English",
volume = "3",
pages = "e1386",
journal = "PeerJ",
issn = "2167-8359",
publisher = "PeerJ Inc.",

}

TY - JOUR

T1 - Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance

AU - Lee, Yi-Chao

AU - Huang, Chi-Chen

AU - Lin, Ding-Yen

AU - Chang, Wen-Chang

AU - Lee, Kuen-Haur

PY - 2015

Y1 - 2015

N2 - Ovarian cancer has a poor prognosis. Most patients are diagnosed with ovarian cancer when the disease has reached an advanced stage and cure rates are generally under 30%. Hence, early diagnosis of ovarian cancer is the best means to control the disease in the long term and abate mortality. So far, cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) are the gold-standard tumor markers for ovarian cancer; however, these two markers can be elevated in a number of conditions unrelated to ovarian cancer, resulting in decreased specifically and positive predictive value. Therefore, it is urgent to identify novel biomarkers with high reliability and sensitivity for ovarian cancer. In this study for the first time, we identified a member of the centromere protein (CENP) family, CENPK, which was specifically upregulated in ovarian cancer tissues and cell lines and the overexpression of which was associated with poor prognoses in patients with ovarian cancer. In addition, the presence of CENPK significantly improved the sensitivity of CA125 or HE4 for predicting clinical outcomes of ovarian cancer patients. In conclusion, we identified that CENPK was specifically upregulated in ovarian cancer cells and can be used as a novel tumor marker of ovarian cancer.

AB - Ovarian cancer has a poor prognosis. Most patients are diagnosed with ovarian cancer when the disease has reached an advanced stage and cure rates are generally under 30%. Hence, early diagnosis of ovarian cancer is the best means to control the disease in the long term and abate mortality. So far, cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) are the gold-standard tumor markers for ovarian cancer; however, these two markers can be elevated in a number of conditions unrelated to ovarian cancer, resulting in decreased specifically and positive predictive value. Therefore, it is urgent to identify novel biomarkers with high reliability and sensitivity for ovarian cancer. In this study for the first time, we identified a member of the centromere protein (CENP) family, CENPK, which was specifically upregulated in ovarian cancer tissues and cell lines and the overexpression of which was associated with poor prognoses in patients with ovarian cancer. In addition, the presence of CENPK significantly improved the sensitivity of CA125 or HE4 for predicting clinical outcomes of ovarian cancer patients. In conclusion, we identified that CENPK was specifically upregulated in ovarian cancer cells and can be used as a novel tumor marker of ovarian cancer.

KW - Journal Article

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-84992153634&origin=resultslist&sort=plf-f&src=s&sid=f3149d4cc800857f9386db46fe0f1187&sot=a&sdt=a&sl=18&s=AU-ID%2826650004100%29&relpos=11&citeCnt=5&searchTerm=

UR - https://www.scopus.com/results/citedbyresults.uri?sort=plf-f&cite=2-s2.0-84992153634&src=s&imp=t&sid=098ddd16ce0462430c2c2a7af7f8850f&sot=cite&sdt=a&sl=0&origin=recordpage&editSaveSearch=&txGid=abd701db3c553d0b7d092e9450bc3ffd

U2 - 10.7717/peerj.1386

DO - 10.7717/peerj.1386

M3 - Article

VL - 3

SP - e1386

JO - PeerJ

JF - PeerJ

SN - 2167-8359

ER -